Clopidogrel and Repaglinide interaction
Clopidogrel and Repaglinide: both prescribing labels flag this combination with the strongest language, such as a contraindication, a boxed warning, or an instruction to avoid it.
Do not combine without a prescriber's guidance. The label language below is the strongest FDA uses.
What the FDA labels say
From the Clopidogrel (Plavix) label · effective 2025-05-30
Avoid concomitant use of repaglinide with Plavix.
If concomitant use cannot be avoided, initiate repaglinide at 0.5 mg before each meal and do not exceed a total daily dose of 4 mg.
Repaglinide (CYP2C8 substrates): Increases substrate plasma concentrations.
Plavix increased repaglinide exposures by 3.9-fold to 5.1-fold [see Clinical Pharmacology (12.3) ] .
Repaglinide (CYP2C8 Substrates) The acyl-β-glucuronide metabolite of clopidogrel is a strong inhibitor of CYP2C8.
From the Repaglinide label · effective 2025-05-02
Clopidogrel Clinical Impact: Clopidogrel increased repaglinide tablets exposures by 3.9-5.1 fold [see Clinical Pharmacology (12.3) ] Intervention: Avoid concomitant use of repaglinide tablets with clopidogrel.
Examples: beta-blockers, clonidine, guanethidine, and reserpine Clopidogrel : Avoid concomitant use; if used concomitantly initiate at 0.5 mg before each meal and limit total daily dose to 4 mg ( 7 )
Taking more than these two? Interactions stack. Check your whole list at once; it stays in your browser.
Open in the checkerNot medical advice. Interaction Checker quotes FDA label text and NIH fact sheets. Whether an interaction matters for you depends on doses, timing, kidney and liver function, and other conditions. Confirm with a pharmacist or prescriber.